2021 Year in Review - Ovarian Cancer

In 2021, the COVID-19 pandemic continued to impact the practice of medicine and dissemination of treatment advances presented in scientific forums.
Results of the primary analysis of the phase 3b OPINION study supported the use of olaparib maintenance therapy in patients with nongermline BRCA1/2-mutated platinum-sensitive relapsed ovarian cancer.
The final overall survival analysis of the phase 2 LIGHT study indicates that olaparib therapy in patients with platinum-sensitive relapsed ovarian cancer provides overall survival benefit across patient cohorts, regardless of BRCA mutation and homologous recombination deficiency status, with a safety profile consistent with that previously described.
Results of the phase 2 EFFORT study support the efficacy of adavosertib, with and without olaparib, in patients with poly (ADP-ribose) polymerase inhibitor–resistant ovarian cancer, with manageable adverse events.
Results of the PAOLA-1/ENGOT-ov25 study demonstrated sustained progression-free survival benefit with the addition of maintenance olaparib to bevacizumab, compared with placebo and bevacizumab in homologous recombination deficiency-positive patients, irrespective of International Federation of Gynecology and Obstetrics stage and residual disease after up-front surgery.
Results of the subgroup analysis of the ARIEL4 study suggest that heavily pretreated patients with advanced relapsed ovarian carcinoma harboring a BRCA1/2 mutation derive progression-free survival benefit from rucaparib treatment across all platinum-sensitivity subgroups.
Five-year follow-up results of the SOLO1 trial indicate that 2 years of maintenance olaparib provides sustained progression-free survival benefit in patients with newly diagnosed advanced ovarian cancer harboring BRCA1 and/or BRCA2 mutations, with no emergence of new safety signals.
Secondary efficacy data and subgroup analyses from the LIGHT study indicate that olaparib monotherapy was most effective in BRCA-mutated cohorts of patients with platinum-sensitive relapsed ovarian cancer.
Results of the ORZORA trial indicate that patients with platinum-sensitive relapsed ovarian cancer derived progression-free survival benefit from maintenance olaparib, irrespective of somatic or germline BRCA mutation status.
Results of the phase 3, randomized ARIEL4 trial demonstrate that patients with BRCA-mutated advanced, relapsed ovarian cancer derive significant progression-free survival benefit from rucaparib therapy compared with standard-of-care chemotherapy, with the emergence of no new safety signals.
Page 1 of 3
Results 1 - 10 of 30

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
    Profession or Role
    Primary Specialty or Disease State

    Please enter your mailing address.

    Address Line 2
    Zip Code